Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOI037)

Drug Name
RG-4934 Drug Info
Synonyms IL-17 huMAb (psoriatic arthritis), Roche
Indication
Disease Entry ICD 11 Status REF
Arthritis FA20 Discontinued in Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMOI037

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Interleukin-17 (IL17)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Brodalumab DMASDQ6 Plaque psoriasis EA90.0 Approved [3]
Bimekizumab DMR9TF1 Plaque psoriasis EA90.0 Approved [4]
Ixekizumab DMXW92T Plaque psoriasis EA90.0 Approved [5]
CNTO-6785 DM6RQXB Rheumatoid arthritis FA20 Phase 2 [6]
ABT-122 DM23UQ9 Psoriatic arthritis FA21 Phase 2 [7]
CJM112 DMTSVJM Acne vulgaris ED80 Phase 2 [8]
COVA322 DM824EG Psoriasis vulgaris EA90 Phase 1/2a [9]
SHR-1314 DMADNY3 Plaque psoriasis EA90.0 Phase 1/2 [4]
ABBV-257 DMCZI8L Rheumatoid arthritis FA20 Phase 1 [10]
ALX-0761 DMJ8ACF Psoriasis vulgaris EA90 Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-17 (IL17) TTG0MT6 IL17_HUMAN Not Available [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032677)
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032677)
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.
6 Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2.
7 DOI: 10.1136/annrheumdis-2015-eular.4042
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)